Clinical significance of two real-time PCR assays for chronic hepatitis C patients receiving protease inhibitor-based therapy

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Inoue, Takako ^a   Hmwe, Su Su ^b   Shimada, Noritomo ^c,d   Kato, Keizo ^d   Ide, Tatsuya ^e   Torimura, Takuji ^e   Kumada, Takashi ^f   Toyoda, Hidenori ^f   Tsubota, Akihito ^g   Takaguchi, Koichi ^h   Wakita, Takaji ^b   Tanaka, Yasuhito ^a,i  

^a NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c Ootakanomori Hospital   (Japan)

^d Shinmatsudo Central General Hospital   (Japan)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f OGAKI MUNICIPAL HOSPITAL   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

ⁱ NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; DACLATASVIR; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; OLIGOPEPTIDE; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; IN VITRO STUDY; JAPAN; MALE; PATIENT ASSESSMENT; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS GENOME; AGED; BLOOD; CELL LINE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; DRUG POTENTIATION; GENETIC TRANSFECTION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; SENSITIVITY AND SPECIFICITY; VIREMIA; VIROLOGY; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; CELL LINE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TRANSFECTION; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 85010822294     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170667     Document Type: Article

References (32)

1. Lee MH, Yang HI, Yuan Y, L'Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20(28):9270-9280. Epub 2014/07/30. PubMed Central PMCID: PMCPmc4110557. doi: 10.3748/wjg.v20.i28.9270 PMID: 25071320
2. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62(1 Suppl):S87-99. Epub 2015/04/29.
3. Seifert LL, Perumpail RB, Ahmed A. Update on hepatitis C: Direct-acting antivirals. World J Hepatol. 2015;7(28):2829-2833. Epub 2015/12/17. PubMed Central PMCID: PMCPmc4670954. doi: 10.4254/wjh.v7.i28.2829 PMID: 26668694
4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416. Epub 2011/06/24. doi: 10.1056/NEJMoa1012912 PMID: 21696307
5. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014-1024. Epub 2011/09/16. PubMed Central PMCID: PMCPmc3809077. doi: 10.1056/NEJMoa1014463 PMID: 21916639
6. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56(1):78-84. Epub 2011/08/11. doi: 10.1016/j.jhep. 2011.07.016 PMID: 21827730
7. Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013;59(2):205-212. Epub 2013/04/02. doi: 10.1016/j.jhep. 2013.03.020 PMID: 23542346
8. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105-1109. Epub 2009/09/15. doi: 10.1038/ng.449 PMID: 19749757
9. McPhee F, Suzuki Y, Toyota J, Karino Y, Chayama K, Kawakami Y, et al. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms. Adv Ther. 2015;32(7):637-649. Epub 2015/07/15. PubMed Central PMCID: PMCPmc4522028. doi: 10.1007/s12325-015-0221-5 PMID: 26155891
10. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-1444. Epub 2011/09/08. PubMed Central PMCID: PMCPmc3229841. doi: 10.1002/hep. 24641 PMID: 21898493
11. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012;32 Suppl 1:2-8. Epub 2012/01/11.
12. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10(5):681-701. Epub 2016/05/28. PubMed Central PMCID: PMCPmc5003900. doi: 10.1007/s12072-016-9736-3 PMID: 27229718
13. Elkady A, Tanaka Y, Kurbanov F, Sugauchi F, Sugiyama M, Khan A, et al. Performance of two Real-Time RT-PCR assays for quantitation of hepatitis C virus RNA: evaluation on HCV genotypes 1-4. J Med Virol. 2010;82(11):1878-1888. Epub 2010/09/28. doi: 10.1002/jmv. 21911 PMID: 20872714
14. Matsuura K, Tanaka Y, Hasegawa I, Ohno T, Tokuda H, Kurbanov F, et al. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. J Clin Microbiol. 2009;47(2):385-389. Epub 2008/12/19. PubMed Central PMCID: PMCPmc2643694. doi: 10.1128/JCM.01753-08 PMID: 19091819
15. Ogawa E, Furusyo N, Murata M, Toyoda K, Eiraku K, Shimizu M, et al. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays. Antiviral Res. 2013;99(2):119-124. Epub 2013/05/21. doi: 10.1016/j.antiviral.2013.05. 002 PMID: 23684903
16. Cloherty G, Cohen D, Sarrazin C, Wedemeyer H, Chevaliez S, Herman C, et al. HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. Antivir Ther. 2015;20(2):177-183. Epub 2014/06/19. doi: 10.3851/IMP2810 PMID: 24941124
17. Ogawa E, Furusyo N, Murata M, Hayashi T, Shimizu M, Mukae H, et al. Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy. Antiviral Res. 2016;126:35-42. Epub 2015/12/23. doi: 10.1016/j.antiviral.2015.12.001 PMID: 26692214
18. Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51(4):1122-1126. Epub 2010/01/14. doi: 10.1002/hep. 23444 PMID: 20069649
19. Halfon P, Khiri H, Gerolami V, Bourliere M, Feryn JM, Reynier P, et al. Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA. J Hepatol. 1996;25(3):307-311. Epub 1996/09/01. PMID: 8895009
20. Watanabe T, Inoue T, Tanoue Y, Maekawa H, Hamada-Tsutsumi S, Yoshiba S, et al. Hepatitis C virus genotype 2 may not be detected by the Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 1.0. J Clin Microbiol. 2013;51(12):4275-4276. Epub 2013/09/27. PubMed Central PMCID: PMCPmc3838077. doi: 10.1128/JCM.02102-13 PMID: 24068011
21. Chevaliez S, Bouvier-Alias M, Castera L, Pawlotsky JM. The Cobas AmpliPrep-Cobas TaqMan realtime polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. Hepatology. 2009;49(4):1397-1398. Epub 2009/03/31. doi: 10.1002/hep. 22767 PMID: 19330876
22. Chevaliez S, Bouvier-Alias M, Rodriguez C, Soulier A, Poveda JD, Pawlotsky JM. The Cobas Ampli-Prep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA. J Clin Microbiol. 2013;51(4):1078-1082. Epub 2013/01/18. PubMed Central PMCID: PMCPmc3666793. doi: 10.1128/JCM.02004-12 PMID: 23325825
23. Leckie G, Schneider G, Abravaya K, Hoenle R, Johanson J, Lampinen J, et al. Performance attributes of the LCx HCV RNA quantitative assay. J Virol Methods. 2004;115(2):207-215. Epub 2003/12/12. PMID: 14667537
24. Germer JJ, Harmsen WS, Mandrekar JN, Mitchell PS, Yao JD. Evaluation of the COBAS TaqMan HCV test with automated sample processing using the MagNA pure LC instrument. J Clin Microbiol. 2005;43(1):293-298. Epub 2005/01/07. PubMed Central PMCID: PMCPmc540141. doi: 10.1128/JCM.43.1. 293-298.2005 PMID: 15634985
25. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11(7):791-796. Epub 2005/06/14. PubMed Central PMCID: PMCPmc2918402. doi: 10.1038/nm1268 PMID: 15951748
26. Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011;204(1):84-93. Epub 2011/06/02. PubMed Central PMCID: PMCPmc3307155. doi: 10.1093/infdis/jir210 PMID: 21628662
27. van den Boorn JG, Schlee M, Coch C, Hartmann G. SiRNA delivery with exosome nanoparticles. Nat Biotechnol. 2011;29(4):325-326. Epub 2011/04/12. doi: 10.1038/nbt.1830 PMID: 21478846
28. Koppers-Lalic D, Hogenboom MM, Middeldorp JM, Pegtel DM. Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine. Adv Drug Deliv Rev. 2013;65(3):348-356. Epub 2012/07/24. doi: 10.1016/j.addr.2012.07.006 PMID: 22820525
29. Chahar HS, Bao X, Casola A. Exosomes and Their Role in the Life Cycle and Pathogenesis of RNA Viruses. Viruses. 2015;7(6):3204-3225. Epub 2015/06/24. PubMed Central PMCID: PMCPmc4488737. doi: 10.3390/v7062770 PMID: 26102580
30. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology. 2002;36(1):211-218. Epub 2002/06/27. doi: 10.1053/jhep. 2002.34130 PMID: 12085367
31. McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Kamae I, et al. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res. 2016;46(5):423-433. Epub 2015/10/07. doi: 10.1111/hepr.12570 PMID: 26440999
32. Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol. 2016;51(7):733-740. Epub 2016/01/16. doi: 10.1007/s00535-016-1162-8 PMID: 26768604